Evidence map›Paper›PMID 19324994›Full record

ArticleThe Journal of molecular diagnostics : JMD2009

Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.

Michael J Brisco, Sue Latham, Rosemary Sutton, Elizabeth Hughes, Vicki Wilczek, Katrina van Zanten, Bradley Budgen, Anita Y Bahar, Maria Malec, Pamela J Sykes and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Minimal Residual Disease Detection and EvolvedFrontiers in immunology · 2016
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Michael J BriscoDepartment of Hematology and Genetic Pathology, Flinders University and Medical Centre, Adelaide, Australia.
Sue Latham
Rosemary Sutton
Elizabeth Hughes
Vicki Wilczek
Katrina van Zanten
Bradley Budgen
Anita Y Bahar
Maria Malec
Pamela J Sykes
Bryone J Kuss
Keith Waters
Nicola C Venn
Jodie E Giles
Michelle Haber
Murray D Norris
Glenn M Marshall
Alexander A Morley
Flinders Medical Centre · AUUNSW Sydney · AUChildren's Cancer Institute Australia · AUFlinders University · AUBoston Children's Hospital · USRoyal Children's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia were identified by determining, at the time of diagnosis, the repertoire of rearrangements of the immunoglobulin heavy chain (IGH) gene using segment-specific variable (V), diversity (D), and junctional (J) primers in two different studies that involved a total study population of 75 children and 18 adults. This strategy, termed repertoire analysis, was compared with the conventional strategy of identifying markers using family-specific V, D, and J primers for a variety of antigen receptor genes. Repertoire analysis detected significantly more markers for the major leukemic clone than did the conventional strategy, and one or more IgH rearrangements that were suitable for monitoring the major clone were detected in 96% of children and 94% of adults. Repertoire analysis also detected significantly more IGH markers for minor clones. Some minor clones were quite large and a proportion of them would not be able to be detected by a minimal residual disease test directed to the marker for the major clone. IGH repertoire analysis at diagnosis has potential advantages for the identification of molecular markers for the quantification of minimal residual disease in acute lymphoblastic leukemia cases. An IGH marker enables very sensitive quantification of the major leukemic clone, and the detection of minor clones may enable early identification of additional patients who are prone to relapse.

Indexed as

Cell LineageGene Rearrangement, B-LymphocyteAdultChildCooperative BehaviorDNA, NeoplasmGenetic MarkersGenome, HumanHumansImmunoglobulin Heavy ChainsNeoplasm, ResidualPrecursor B-Cell Lymphoblastic Leukemia-LymphomaDNA, NeoplasmGenetic MarkersImmunoglobulin Heavy Chains

Identifiers

PMID19324994
PMCPMC2671336
OpenAlexW2125202362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.